Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway
Usp7 protects genomic stability by regulating Bub3
Usp7 and Uhrf1 Control Ubiquitination and Stability of the Maintenance DNA Methyltransferase Dnmt1
Usp9x-and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells
Usp9x-deficiency disrupts the morphological development of the postnatal hippocampal dentate gyrus
Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma
UspB, a member of the sigma-S regulon, facilitates RuvC resolvase function
Ussing Chamber技术在家禽肠道营养物质转运研究中的应用
Ussing chamber技术在药物肠吸收方面的应用进展
Ussing Chamber模型研究甘草酸二铵经大鼠肠黏膜的转运和代谢
Ussing's conundrum and the search for transport mechanisms in plants
Ussing's "little chamber": 60 years+ old and counting
Ussing chamber在肠道屏障功能研究中的进展
ustained effect of resistance training on blood pressure and hand grip strength following a detraining period in elderly hypertensive women: a pilot study
ustainability of hydrogen supply chain. Part I: Identification of critical criteria and cause-effect analysis for enhancing the sustainability using DEMATEL
Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: A meta-analysis
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial
Ustekinumab治疗斑块状银屑病疗效和安全性的分析
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
Ustekinumab Treatment for Psoriasis in 119 Patients Maintained on Therapy for a Minimum of One Year: A Review
Ustekinumab for psoriatic arthritis: close to the PSUMMIT?
Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement
Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis
Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study
Ustekinumab for the treatment of Crohn's disease
Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients
Ustekinumab Improves Psoriasis without Suppressing Tumor Antigen-Specific Cytotoxic T Lymphocytes
Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study
Ustekinumab in the Treatment of Refractory Chronic Cutaneous Lupus Erythematosus: A Case Report